Multiple Myeloma Therapeutics: Market Research Report

Date: October 22, 2011
Pages: 595
Price:
US$ 4,500.00
Publisher: Global Industry Analysts, Inc
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: ME3D3F95CC6EN
Leaflet:

Download PDF Leaflet

Multiple Myeloma Therapeutics: Market Research Report
This report analyzes the worldwide markets for Multiple Myeloma Therapeutics in US$ Million.

The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World.

Annual estimates and forecasts are provided for the period 2009 through 2017.

A six-year historic analysis is also provided for these markets.

The report profiles 75 companies including many key and niche players such as Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, F.Hoffmann-la Roche Ltd, Genentech, Inc., Janssen Biotech, Inc., Millennium Pharmaceuticals, Seattle Genetics, and Ziopharm Oncology, Inc.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

2. INDUSTRY OVERVIEW

Robust Growth Ahead for Myeloma Therapeutics Market
Multiple Myeloma: A Second Most Common Hematological Cancer

Table 1. Global Multiple Myeloma Disease Statistics: 2010 (includes corresponding Graph/Chart)
Table 2. Global Multiple Myeloma Patient Population in Thousands under Treatment by Treatment Stage: 2010 (includes corresponding Graph/Chart)
Table 3. Leading Companies in the Global Oncology Therapy Market (2010): Percentage Market Share Breakdown of Revenues for Roche, Novartis, Amgen, AstraZeneca, sanofi-aventis, Celgene, and Others (includes corresponding Graph/Chart)

US Remains the Largest Market; Rest of World to Spearhead Growth

3. MULTIPLE MYELOMA DRUGS MARKET – AN OVERVIEW

The Myeloma Drug Domain

Table 4. Annual Revenues of Select Multiple Myeloma Drugs Worldwide: 2008 & 2009 (In US$ Million) (includes corresponding Graph/Chart)

Revlimid Outshines Other Leading Drugs
Velcade – Still the Most Superior in terms of Survival Rate

Table 5. Sales of Velcade in the US and Rest of World: 2008 & 2009 (In US$ Million) (includes corresponding Graph/Chart)

Subcutaneous Infusion – A Refuge for Velcade from Nueropathy?
Unmet Needs Drive Further Innovation in the Therapeutic Area
Promising Drugs on the Anvil, Potential Market Remains Uncertain
Revlimid – A Key Revenue Generator for Celgene

Table 6. Sales of Revlimid in the US and Rest of World: 2009 & 2010 (In US$ Million) (includes corresponding Graph/Chart)
Table 7. Sales of Thalomid in the US and Rest of World: 2009 & 2010 (In US$ Million) (includes corresponding Graph/Chart)

Doxil Regains Sales Momentum
Treatment Therapies: Move Up the Learning Curve
Risk-Adapted Therapy: The New Norm of Future Treatment
New Generation Drugs in the Arsenal Against Multiple Myeloma
Revlimid® (lenalidomide)
Velcade® (bortezomib)
Thalomid® (thalidomide)
Doxil (liposomal doxorubicin)
Alkeran (melphalan)
Trisenox® (arsenic trioxide)
Select Promising Pipeline Drugs
Carfilzomib (Onyx Pharmaceuticals)
Phase II Results of Carfilzomib
Pomalidomide (Celgene)
Noteworthy Issues Related to Major Drugs: An Evaluation of Pros and Cons
Revlimid Overtakes Thalomid: Why?
How Effective Will Thalomid Be in the 3rd Line Setting? Skepticism Overflows…
Revlimid Impedes Stem Cell Harvesting!!: What’s the Truth?
Other Trends & Issues
Approval of New Generation Drugs Push the Market Into the Bulge Bracket
Growth Fundamentals Get Stronger
Multidrug Resistance: A Challenge to Reckon With
Gene Therapy Exudes Hope

4. CLINICAL TRIALS FOR MULTIPLE MYELOMA

Focus on Select Mid- and Late-Stage Clinical Trials in Multiple Myeloma
Lenalidomide versus Placebo Maintenance Treatment post Single AHSCT for Myeloma
Lenalidomide Maintenance Therapy Post Stem Cell Transplantation for Myeloma
Doxorubicin + Bortezomib + Dexamethasone versus VAD Ensued by High-Dose Melphalan and Maintenance with Thalidomide/Bortezomib in Newly Diagnosed MM Patients….
Weekly Bortezomib Maintenance Therapy Following Bortezomib-based Induction Therapy in Recently Diagnosed, Aged MM Sufferers………. .
Lenalidomide in Combination with Prednisone and Melphalan in Recently Diagnosed Patients Above 65 years of Age……….
Bortezomib + Prednisone + Melphalan, and Thalidomide Ensued by Thalidomide + Bortezomib Maintenance for Preliminary Treatment of Aged MM Patients
Lenalidomide + Dexamethasone + Carfilzomib in Recently Diagnosed Multiple Myeloma
Carfilzomib in Refractory and Relapsed MM Setting
Carfilzomib as Standalone Therapy in Relapsed or Refractory MM
Combination of Vorinostat and Lenalidomide + Bortezomib in Relapsed/Refractory Multiple Myeloma
Carfilzomib in Refractory/Relapsed MM Patients (for Long-Term Tolerability and Treatment)
Multiple Myeloma Drugs In Pipeline in the Us As of the Year 2008
Phase III Drugs in Pipeline
Phase II Drugs in Pipeline
Phase I Drugs in Pipeline

5. HEMATOLOGICAL CANCERS – AN OVERVIEW & THERAPIES

Hematological Cancer Therapies: A Prelude
Treatment Regimes: The Golden Rule
Challenges Encountered in Clinical Trials
FDA’s Antidotes

6. DISEASE & TREATMENT OVERVIEW

Cancer: A Definition
Hematological Cancers
Types of Hematological Cancer
Multiple Myeloma
Multiple Myeloma Stages
Stage I
Stage II/III
Treatment Procedures
Diagnosis
Treatment
Initial Treatment Regimen
Induction Therapy for SCT Candidates
Induction Therapy for Non-SCT Candidates
Therapy for Relapsed or Refractory Myeloma
Maintenance Therapy for Relapsed or Refractory Myeloma
Treatment Pros & Cons
Other Types of Hematological Cancers
Leukemia
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Acute Myeloid Leukemia
Chronic Myeloid Leukemia
Lymphoma
Non-Hodgkin’s Lymphoma
Hodgkin’s Lymphoma
Myelodysplastic Syndromes
Hematological Cancer Therapies
Chemotherapy
Radiation Therapy
Stem Cell Transplants
Biological Therapy
Targeted Therapy
Gene Therapy
Immunotherapy
Monoclonal Antibody Treatment
Vaccines
Donor Lymphocyte Infusion
Hematological Cancer Drug Classes
Hypomethylating Agents & Antimetabolites
Bisphosphonates
Alkylating Agents and DNA-Damaging Agents
DNA-Repair Enzyme Inhibitors
Histone Deacetylase Inhibitor
Immunomodulators
Proteasome Inhibitor
Tyrosine Kinase Inhibitors

7. DRUG APPROVALS/LAUNCHES

Celgene Launches Revlimid and Lenadex Drugs in Japan
Millennium Receives FDA Approval for Supplemental NDA of VELCADE
Intas Introduces Bortezomib Injection for Treating Multiple Myeloma in India
NICE Grants Approval for Use of Revlimid®
SWOG Announces Closure of Phase III Trial (S0232) for Paitents with Multiple Myeloma
Fujimoto Pharmaceutical Receives Approval to Market Thalidomide
Celgene Obtains Health Canada Approval for Revlimid Oral Cancer Drug
FDA Grants Orphan-Drug Designation to Melphalan
Merck Commences Phase II-b and Phase III Clinical Trial of Zolinza
Clavis Initiates Phase II Trial of Elacytarabine
Gilead Sciences Commences GS 9219 Phase I Clinical Trial
AstraZeneca Carries Out AZD 0530 Phase II trial
European Commission Grants Approval of Thalidomide for Multiple Myeloma
EMEA Issues Positive Opinion for Thalidomide Use in Multiple Myeloma
Global Regulatory Developments for the Use of Revlimid® in Multiple Myeloma
Takeda Gains FDA Approval to Promote Velcade
Health Canada Approves VELCADE
Genzyme Receives FDA Certification for Mozobil
Celgene’s Thalidomide Pharmion Receives Marketing Authorization
Ziopharm Commences Phase II Clinical Trial of ZIO-101
FDA Approves Pluristem’s Pre-IND Application of PLX-I
Merck Pharmaceuticals Commences Phase I Study for R763 Kinase Inhibitor
Swissmedic Approves Celgene’s REVLIMID Oral Cancer Drug
Celgene’s REVLIMID Receives EU’s Marketing Authorization
FDA Approves Application of Piramal’s IND-P276 Multiple Myeloma Drug
Millennium Pharmaceuticals and Johnson & Johnson Initiate Velcade® Phase II Trial
FDA to Consider the New Drug Application Filed for Use of Doxil® Combined with Velcade® in Patients with Multiple Myeloma
Ortho Biotech Files Application with FDA for Approval of Combination Drug DOXIL® and VELCADE®
Caraco’s Allopurinol Receives FDA Approval
FDA Approves Thalomid® as Combination Therapy for Multiple Myeloma
Revlimid® Obtains Regulatory Approval for the Treatment of Multiple Myeloma
LymphoSign Inc. Announces Successful Completion of LS104 Drug’s Pre-Clinical Testing
Seattle Genetics Commences SGN-40 Phase I Clinical Trial
FDA Approves Use of Revlimid® for Multiple Myeloma
US FDA Approves Use of Thalidomide for Multiple Myeloma
Ziopharm Oncology Receives Approval to Commence ZIO-101 and ZIO-201 Trial
FDA Grants Approval for Use of VELCADE® for Patients with Mantle Cell Lymphoma

8. RECENT INDUSTRY ACTIVITY

Onyx Files NDA for Carfilzomib in Myeloma Treatment
XTL Gains Orphan Drug Designation for rHuEPO
Signal Genetics Enters into a Commercialization Agreement with NeoGenomics Laboratories
The Leukemia & Lymphoma Society Forms Alliance with Acetylon Pharmaceuticals
Onyx Pharmaceuticals Gains FDA Fast Track Designation for Carfilzomib
MMRF Enters into Collaboration with Astellas Pharma
Takeda and Millennium Submit Two sNDA to FDA for Bortezomib
Astex Enters into Definitive Merger Agreement with SuperGen
Yakult Honsha Enters into an Agreement with Aeterna Zentaris
Celgene Submits MAA for REVLIMID in Europe
BMS Halts Tanespimycin Development
Acetylon Releases Pre-Clinical Data for ACY-1215 in Multiple Myeloma
Intellikine and MMRC Initiate Phase I Clinical Trial of INK128
Celgene Gains MHLW Approval for REVLIMID in Japan
XTL Acquires Bio-Gal
Compugen Discovers New Drug Target for Treating Multiple Myeloma
Boehringer Ingelheim Enters into a Collaboration Agreement with Micromet
Abbott Acquires Facet Biotech
Mannkind Enters Into a Research Agreement with MMRF
Genentech Terminates Collaboration Agreement with Seattle for SGN-40
Keryx Gains Fast Track Designation for Perifosine from FDA
FDA Clears Perifosine for Phase III Clinical Trials in Multiple Myeloma
CyDex Receives FDA Approval for Clinical Evaluation of CDX-353
Onyx Acquires Proteolix
Johnson & Johnson to Acquire Cougar
Janssen and Takeda Ink Co-Promotion Agreement
Eisai Establishes Subsidiary in Canada
Roche Group and ImmunoCellular Therapeutics Ink Licensing Agreement
CytRx Acquires Innovive
Launch of Epoetin alfa Hexal
PDL and Bristol-Myers Signs Agreement
MNKD and LLS Conclude Joint Research Agreement
MorphoSys and DSM Enter into Agreement
StemCyte Enters into Joint Venture with Cadila and Apollo Hospitals in India
ImmunoCellular Acquires Molecular Antibody Technology
US House of Representatives Sanction the Hematological Cancer Research Investment and Education Act
Bayer and Cell Therapeutics Enter into Mutual Agreement
Bristol-Myers Takes Over Kosan Biosciences
Bristol and PDL BioPharma Enter into Agreement
Gamida Cell Enters Into a Agreement with Amgen
Circadian Acquires Complete Stake in Vegenics
Takeda Acquires Millennium Pharmaceuticals
Access Pharmaceuticals Acquires Somanta
Celgene Acquires Pharmion
GlaxoSmithKline Forms Alliance with OncoMed for Developing Cancer Therapeutics
Cyclacel Acquires ALIGN Pharmaceuticals
Biogen and Genentech to Jointly Develop and Commercialize New Blood Cancer Drug
Aegera Therapeutics Acquires LymphoSign Inc
Velcade Gains Subsidy
Inex Pharmaceuticals Spins Off Biotechnology Business into Tekmira Pharmaceuticals
MilleGen Enters into Collaboration with LFB
TopoTarget Acquires Apoxis SA
Genentech Inks Exclusive Global Licensing Agreement with Seattle Genetics
PerkinElmer Takes Over ViaCell
Favrille Announces Acquisition of Monoclonal Antibody Range from Diversa
Johnson & Johnson Secures Contract worth US$112 Million
Bioniche Pharma Acquires Branded Pharmaceutical from Nabi Biopharmaceuticals
Takara Bio's RetroNect Used for Clinical Trials of Gene Therapy in Australia
MDS Pharma Services Becomes Recommended CRO for Multiple Myeloma Drug R&D
Celgene Certifies McKesson Specialty to Launch Revlimid
Medarex and PacMab to Co-Develop Blood Cancer Therapies
Gamida Cell and Teva to Co-Develop Therapy for Hematological Malignancies
GlaxoSmithKline Takes Over Praecis Pharmaceuticals
Biotest Acquires ImmunoGen Anticancer Technology Rights
Hana Signs Licensing Agreement with Inex
Cephalon Acquires Zeneus

9. FOCUS ON SELECT PLAYERS

Amgen, Inc. (USA)
Bristol-Myers Squibb Company (USA)
Celgene Corporation (USA)
F. Hoffmann-La Roche Ltd (Switzerland)
Genentech, Inc. (USA)
Janssen Biotech, Inc. (USA)
Millennium Pharmaceuticals (USA)
Seattle Genetics (USA)
Ziopharm Oncology, Inc. (USA)

10. GLOBAL MARKET PERSPECTIVE

Table 8. World Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 9. World Historic Review for Multiple Myeloma Therapeutics by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 10. World 15-Year Perspective for Multiple Myeloma Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

11. THE UNITED STATES

A. MARKET ANALYSIS

Current & Future Analysis
US Myeloma Statistics

Table 11. Multiple Myeloma Disease Statistics in the US: 2010 (includes corresponding Graph/Chart)
Table 12. Addressable Multiple Myeloma Patient Population in the US by Treatment Stage: 2010 (includes corresponding Graph/Chart)
Table 13. Hematological Malignancies in the US (2009): Number of Incidences by Type of Cancer - Lymphoma (Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma), Multiple Myeloma, Leukemia (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, and Other Leukemia) (includes corresponding Graph/Chart)
Table 14. Hematological Malignancies in the US (2009): Number of Deaths by Type of Cancer - Lymphoma (Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma), Multiple Myeloma, Leukemia (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, and Other Leukemia) (includes corresponding Graph/Chart)
Table 15. Blood Cancer Statistics in the US (2010): Percentage Breakdown of Hematological Cancer Cases by Type: Lymphoma, Myeloma, and Leukemia (includes corresponding Graph/Chart)

Trends in Myeloma Therapeutics in the US
Doctors Shift to Continuous Therapy in Myeloma Treatment

Table 16. Key Drug Regimens in the US Multiple Myeloma Market (2006): Breakdown of Typical Length of Treatment Cycle and Cost per Cycle (In US$) (includes corresponding Graph/Chart)

Market Share Statistics

Table 17. Market Share Breakdown of Major Multiple Myeloma Drug Regimens in the US in First Line Setting by Number of Patients on Treatment: 2010 (includes corresponding Graph/Chart)
Table 18. Market Share Breakdown of Major Multiple Myeloma Drug Regimens in the US in Relapsed/ Refractory Setting by Number of Patients on Treatment: 2010 (includes corresponding Graph/Chart)
Table 19. US Market for Multiple Myeloma Therapeutics (2010): Percentage Market Share Breakdown of Revenues by Company - Celgene Corporation, Millennium Pharmaceuticals and Others (includes corresponding Graph/Chart)

Key Non-Profit Organizations in the US
Multiple Myeloma Research Foundation (MMRF)
National Coalition for Cancer Survivorship (NCCS)
National Marrow Donor Program (NMDP)
Oregon Health and Science University Cancer Institute
Drug Approvals
Strategic Corporate Developments
Focus on Select Key Players

B. MARKET ANALYTICS

Table 20. The US Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 21. US Historic Review for Multiple Myeloma Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

12. JAPAN

A. MARKET ANALYSIS

Current & Future Analysis
Myeloma in Japan

Table 22. Multiple Myeloma Disease Statistics in Japan: 2010 (includes corresponding Graph/Chart)
Table 23. Addressable Multiple Myeloma Patient Population in Japan by Treatment Stage: 2010 (includes corresponding Graph/Chart)

Drug Launches
Strategic Corporate Developments

B. MARKET ANALYTICS

Table 24. Japanese Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 25. Japanese Historic Review for Multiple Myeloma Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

13. EUROPE

A. MARKET ANALYSIS

Current & Future Analysis
Myeloma in the EU – A Statistical Review

Table 26. Multiple Myeloma Disease Statistics in the EU: 2010 (includes corresponding Graph/Chart)
Table 27. Addressable Multiple Myeloma Patient Population in the EU by Treatment Stage: 2010 (includes corresponding Graph/Chart)
Table 28. Market Share Breakdown of Major Multiple Myeloma Drug Regimens in the EU in First Line Setting by Number of Patients on Treatment: 2010 (includes corresponding Graph/Chart)
Table 29. Market Share Breakdown of Major Multiple Myeloma Drug Regimens in the EU in Relapsed/ Refractory Setting by Number of Patients on Treatment: 2010 (includes corresponding Graph/Chart)

Europe Lagging Behind in Drug Approvals
Thalidomide Takes Rebirth in the UK NHS
Strategic Corporate Developments
F. Hoffmann-La Roche Ltd (Switzerland) – A Key Player

B. MARKET ANALYTICS

Table 30. European Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 31. European Historic Review for Multiple Myeloma Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

14. REST OF WORLD

A. MARKET ANALYSIS

Current & Future Analysis
Strategic Corporate Developments
Drug Launch

B. MARKET ANALYTICS

Table 32. Rest of World Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 33. Rest of World Historic Review for Multiple Myeloma Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE

Total Companies Profiled: 75 (including Divisions/Subsidiaries - 80)
Region/CountryPlayers
The United States56
Canada
Japan
Europe
Germany
The United Kingdom
Italy
Spain
Rest of Europe
Asia-Pacific (Excluding Japan)
Middle-East
Skip to top


Multiple Myeloma Therapy Area Pipeline Report US$ 1,495.00 Sep, 2010 · 672 pages
Multiple Sclerosis Therapeutics: Market Research Report US$ 3,950.00 Apr, 2010 · 430 pages

Ask Your Question

Multiple Myeloma Therapeutics: Market Research Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: